A groundbreaking study from the University of Gothenburg has found that a brain imaging technology called tau-PET can significantly improve the early diagnosis of Alzheimer’s disease. This advanced technique detects the accumulation of tau protein, a key biomarker of the disease, even in individuals who have yet to exhibit symptoms.
Tau-PET Now Approved for Clinical Use
Previously used mostly for research, tau-PET is now approved for clinical practice by both European and U.S. regulatory authorities. The study, the largest of its kind globally, analyzed data from over 6,500 individuals across 13 countries as part of a major international collaboration. Researchers used the approved tau-PET imaging method to interpret brain scans and evaluate Alzheimer’s risk.
Early Signs Found in Healthy Older Adults
As reported by medicalxpress, the study, published in JAMA, revealed that 10% of healthy individuals around the age of 75 already showed high levels of tau protein in their brains. Notably, this occurred even in the absence of memory loss or cognitive decline. Researchers observed that tau accumulation increased with age and worsening memory function.
Among people with elevated levels of both tau and amyloid proteins, the risk of developing mild cognitive impairment or dementia within five years was 57%. For those who already experienced mild memory problems, the risk surged to 70%.
Clinically Relevant and Predictive Tool
Professor Michael Schöll is the study’s principal investigator and a professor of molecular medicine at the Sahlgrenska Academy. He emphasized the clinical value of tau-PET.
“When both tau and amyloid are present in the brain, the risk of developing Alzheimer’s increases significantly. Tau-PET gives us a clear window into disease progression, helping guide early treatment decisions and improve participant selection in clinical trials,” he explained.
Complementary Role to Blood Tests
Although blood-based tests for amyloid protein are emerging as accessible tools in diagnosing suspected Alzheimer’s, researchers argue that tau-PET provides essential, complementary insights. While blood tests may indicate amyloid buildup, tau-PET offers a detailed view of how far the disease has progressed and what outcomes to expect.
Strongest Biomarker Yet for Alzheimer’s Risk
Alexis Moscoso Rial, the study’s lead author and a researcher at the Sahlgrenska Academy, highlighted the method’s reliability:
“Tau-PET is the most robust biomarker available. It accurately identifies individuals with Alzheimer’s-related brain changes. It also helps predict who is most likely to develop memory loss and dementia.”
A Promising Future for Alzheimer’s Diagnostics
With tau-PET’s integration into clinical care, healthcare providers can detect Alzheimer’s disease earlier and more accurately. This advancement paves the way for timely intervention and personalized care. It also enables more targeted research, potentially transforming how the world approaches this debilitating condition.